- Eslicarbazepine acetate data shows seizure freedom in 41.3% of patients at 12 months, and retention rates of 73.4%.1
- Results from the Euro-Esli study will be presented today at the 32nd International Epilepsy Congress (IEC) in Barcelona, Spain.1
Porto, Portugal | Hatfield, UK | Tuesday 5 September 2017 – Bial and Eisai today announce data which confirm the effectiveness and tolerability of Zebinix® (eslicarbazepine acetate) in routine clinical practice, thereby complementing evidence from clinical trials.[i] The Euro-Esli study is an exploratory pooled analysis of data from 14 European clinical practice studies, analysing data of 2,058 patients aged between 14-88 years old with partial-onset seizures (POS), with or without secondary generalisation.1 Full results will be presented today at the IEC in Barcelona, Spain.1
“It is most reassuring to see similar efficacy results with eslicarbazepine acetate in a routine clinical setting compared to that of clinical trials; we can be confident that this treatment is effective amongst the diversity of our ‘real’ epilepsy patients,” explains Dr Vicente Villanueva, Neurologist and Epileptologist, Hospital Universitario y Politécnico La Fe, Valencia, Spain. “Real-world studies like the Euro-Esli study are important because they provide significant insight into how a drug performs in a routine medical setting, allowing us to assess the drug, to ultimately improve patient outcomes.”
Epilepsy is one of the most common neurological conditions in the world, affecting approximately six million people in Europe.2 An epileptic seizure is a clinical manifestation of the condition, thought to result from an abnormal discharge of a set of neurons in the brain.[ii]Seizures can vary in manifestation, from brief lapses of attention to severe and prolonged convulsions.[iii] Depending on the type, seizures may involve one part of the body or the whole body, and may affect consciousness.3 Seizures can also vary in frequency from less than one per year, to several per day.3 Epilepsy has many possible causes but often the cause is unknown.3
The Euro-Esli study (in over 2,000 patients with epilepsy) showed that at 3, 6 and 12 months, seizure freedom rates in patients aged 14-88 years treated with eslicarbazepine acetate were 30.6%, 38.3% and 41.3% respectively. Retention rates were 95.4%, 86.6% and 73.4% and responder rates were 60.9%, 70.5% and 75.6%, respectively.1 There were significant reductions from baseline to final visit in monthly frequencies of total (mean reduction 44.1%), simple partial (78.8%), complex partial (53.1%) and secondarily generalised (80.0%) seizures (p<0.001 for all).1 Adverse events were reported for 34.0% of patients and led to discontinuation of 13.6% of patients.1 The most frequently reported adverse events were dizziness (6.7%), fatigue (5.4%) and somnolence (5.1%).1
“These results improve our knowledge and understanding around the use of eslicarbazepine acetate in routine clinical practice and strengthen Bial’s commitment to developing and delivering beneficial treatment options for people living with epilepsy,” comments António Portela, CEO of Bial.
“These data underscore our commitment to our anti-epileptic drug product portfolio. We will continue to invest both in clinical trials and the generation of real-world evidence to improve the lives of patients living with epilepsy,” comments Neil West, Vice President EMEA, Global Neurology Business Unit at Eisai.
Eslicarbazepine acetate is indicated as monotherapy in the treatment of POS, with or without secondary generalisation, in adults with newly diagnosed epilepsy; and as adjunctive therapy in adults, adolescents, and children aged above six years, with POS with or without secondary generalisation.[iv]